Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 51

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 3
Chunk 51
---
aceuticals.. We will continually evaluate Thorium-228 manufacturers and
suppliers and intend to have redundant suppliers prior to the commercial launch of the Alpha DaRT technology, if approved. While we consider
Thorium-228 to be readily available, there can be no guarantee that we will be able to secure another Thorium-228 supplier or obtain on
terms that are acceptable to us.

Our ability to conduct clinical
trials to advance our Alpha DaRT technology is dependent on our ability to obtain the radioisotope Thorium-228 and other isotopes we may
choose to utilize in the future. Currently, we are dependent on third-party manufacturers and suppliers for our isotopes. These suppliers
may not perform their contracted services or may breach or terminate their agreements with us, or may provide a product not of sufficient
quality to allow successful use in our manufacturing processes. Our suppliers are subject to regulations and standards that are overseen
by regulatory and government agencies and we have no control over our suppliers’ compliance to these standards. Failure to comply
with regulations and standards may result in their inability to supply isotope could result in delays in our clinical trials, which could
have a negative impact on our business. We have developed intellectual property, know-how and trade secrets related to the manufacturing
process of the Alpha DaRT technology.

We may form or seek collaborations or strategic
alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such collaborations, alliances
or licensing arrangements.

We have formed and may continue
to form or seek strategic alliances, create joint ventures or collaborations, or enter into additional licensing arrangements with third
parties that we believe will complement or augment our development and commercialization efforts with respect to our Alpha DaRT technology
and any future products or product candidates that we may develop. Any of these relationships may require us to incur non-recurring and
other charges, increase our near and long-term expenditures, issue securities that dilute our existing shareholders or disrupt our management
and business.

In addition, we face significant
competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. We may not be successful
in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed
to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having
the requisite potential to demonstrate safety, potency and quality and obtain marketing authorization or certification.

Further, collaborations involving